Taylor Schreiber, chief scientific officer and co-founder of Shattuck Labs, has been promoted to CEO. He succeeds Josiah Hornblower, who will continue to advise Shattuck as executive chairman of the company’s board of directors. Founded in 2016, Austin, TX-based Shattuck is developing “fusion protein” therapies to treat cancer. The company’s most advanced program, SL-279252, is in early-stage testing under a partnership with Takeda Pharmaceutical (NYSE: [[ticker:TAK]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
